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ABSTRACT 
The aim of this paper is to discuss the enantiomer-specific fate of chiral drugs during wastewater 
treatment and in receiving waters. Several chiral drugs were studied: amphetamine-like drugs of abuse 
(amphetamine, methamphetamine, MDMA, MDA), ephedrines (ephedrine and pseudoephedrine), 
antidepressant venlafaxine and beta-blocker atenolol. A monitoring programme was undertaken in 7 
WWTPs (utilising mainly activated sludge and trickling filters technologies) and at 6 sampling points in 
receiving waters over the period of 9 months. The results revealed enantiomer-specific fate of all studied 
drugs during both wastewater treatment and in the aqueous environment. The extent of stereoselectivity 
depended on several parameters including: type of chiral drug (high stereoselectivity was recorded for 
atenolol and MDMA), treatment technology used (activated sludge showed higher stereoselectivity than 
trickling filters) and season (higher stereoselectivity was observed in the aqueous environment over the 
spring/summer time).  
 
KEYWORDS: chiral, illicit, drugs of abuse, pharmaceuticals, wastewater, environment, river, 
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1. Introduction 
Chiral drugs of abuse including illicit amphetamine-like compounds and abused prescription 
medications such as antidepressants are regarded as new environmental contaminants. Amphetamines 
are frequently found in rivers at levels reaching 50 ng/L. Concentrations of amphetamine-like 
compounds in wastewater were found to vary between a few ng/L and <0.5 μg/L in different wastewater 
treatment plants and different countries and are a reflection of local drug abuse trends (1,2). Due to the 
limited extent of research undertaken in this field, there is minimal understanding of the environmental 
fate and ecotoxicity for these compounds. The phenomenon of chirality of drugs of abuse has also been 
overlooked by environmental researchers and has to be considered as it is a major parameter 
determining the potency and possible toxicity of chiral drugs (2,3). This aspect of environmental studies 
concerning pharmacologically active compounds has been recently reviewed by Kasprzyk-Hordern (2). 
A chiral molecule usually has at least one chiral centre (e.g. asymmetric carbon) as a result of which it 
shows optical activity. It exists in the form of two enantiomers, being the non-superimposable mirror 
images of each other. Enantiomers of the same drug have similar physico-chemical properties but may 
differ in their biological properties. Distribution, metabolism and excretion usually favour one 
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enantiomer over the other. This results from the fact that enantiomers stereoselectively react in 
biological systems, for example with enzymes. Additionally, due to different biological activity, chiral 
drugs can differ in toxicity. Therefore, the enantiomeric composition of chiral drugs can change 
significantly after its administration, followed by metabolism in and excretion from the body. It can be 
subsequently altered during wastewater treatment and as a result of biodegradation processes in the 
environment. These processes can lead to stereoselective enrichment or depletion of enantiomeric 
composition of chiral drugs. Therefore the very same drug might have different activity and toxicity and 
this will depend on its origin and exposure to factors governing its fate in the environment (2, 3). 
Furthermore, the environmental fate and toxicity of chiral drugs are currently assessed without taking 
into consideration their enantiomeric form. This might lead to a significant under or overestimation of 
toxicity of chiral drugs and to incorrect environmental risk assessment as chiral drugs will very likely be 
present in the environment in their non-racemic forms. Fluoxetine is a great example. It is the most toxic 
human pharmaceutical reported so far. Its toxicity is currently assessed for the racemate. However, 
recent research indicates that toxic effects of fluoxetine are enantiomer dependent: S-fluoxetine is 9.4 
times more toxic than R-fluoxetine in Pimephales promelas (11). This enantiomer dependent toxicity of 
fluoxetine is of vital importance if fluoxetine is not released to the environment in a racemic form. 
According to preliminary studies undertaken by MacLeod et al. (8), raw sewage was found to be 
enriched with R(-)-fluoxetine, but after treatment the enantiomeric ratio of fluoxetine’s enantiomers 
changed and led to an enrichment of fluoxetine with S(-)-enantiomer, which is more potent and toxic to 
certain organisms. Additionally, as fluoxetine was also found in tap water (2), actual human exposure to 
this compound might be higher than expected due, primarily, to the presence of a more potent 
enantiomer. Therefore to understand and predict the mechanisms governing the fate of chiral drugs, 
their possible toxicity and impact on the environment, their enantiomeric profiling in environmental 
matrices is essential. Unfortunately no reports exist on the enantiomeric analysis of chiral drugs of abuse 
in the environment and only a few reports are available on the analysis of chiral pharmaceuticals (beta-
blockers, NSAIDs and antidepressants) in environmental matrices (4-10) and on ecotoxicity studies (11-
12).  
This paper is, to the authors’ knowledge, the first study aiming at enantiomeric profiling of chiral drugs 
of abuse during wastewater treatment and in receiving waters. It also discusses the enantiomer-specific 
fate of beta-blocker atenolol in the aqueous environment and during wastewater treatment. 
2. Experimental  
2.1. Chemicals and materials 
Reference standards: R/S(±)-amphetamine (R/S(±)-AMPH), R/S(±)-methamphetamine (R/S(±)-METH), 
1R,2S(-)-ephedrine (1R,2S(-)-EPH), 1S,2R(+)-ephedrine (1S,2R(+)-EPH), 1S,2S(+)-pseudoephedrine 
(1S,2S(+)-PSEUDOEPH), 1R,2R(-)-pseudoephedrine (1R,2R(-)-PSEUDOEPH), R/S(±)-MDA (3,4-
methylenedioxyamphetamine), R/S(±)-MDMA (4-methylenedioxymethamphetamine), R/S(±)-
venlafaxine and R/S(±)-atenolol (Tab. S1) were purchased from LGC Standards (Teddington, UK) and 
Sigma-Aldrich (Gillingham, UK). Enantiomerically pure standards of amphetamine and 
methamphetamine were obtained from LGC Standards. Internal standards (IS): R/S(±)-amphetamine-
d11, R/S(±)-methamphetamine-d14, R/S(±)-MDMA-d5, R/S(±)-MDA-d5 were purchased from LGC 
standards (Teddington, UK). All internal standards were added to the samples before extraction and 
were also used for the quantification of the analytes. 
2.2. Sampling 
Wastewater samples (both influent and effluent) were collected from 7 WWTPs utilising either 
activated sludge or trickling filter bed technologies and 6 locations alongside a river receiving treated 
wastewater from all studied WWTPs (Tab. S2, Fig. S1). Grab samples were collected over the period of 
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9 months (December 2009 – August 2010) during 6 sampling campaigns in order to understand the 
impact seasons might have on enantiomer-specific fate of drugs resulting from different microbial 
activity in different seasons. Grab sampling was chosen as opposed to widely used composite sampling 
due to the possibility of enantiomer-specific degradation of drugs occurring during 24h composite 
sampling time. Significant degradation of several drugs of abuse was observed in another study 
conducted by the authors (33) during 24h experiments imitating composite sampling, which undermines 
the validity of this sampling technique.  
Samples (2 per each sampling point during every sampling campaign) were collected in 2.5 L silanized 
glass amber bottles with teflon faced phenolic caps and filtered through GF/D 2.7 μm followed by GF/F 
0.7 μm glass fibre filters (Whatman, UK). The sample collection times within plants were not adjusted 
for plant hydraulic residence times. 
2.3. Sample preparation and analysis 
Two methodologies were used to identify and quantify chiral drugs in environmental matrices. SPE-
chiral-LC-MS/MS was used only for the verification of enantiomeric fractions of chiral drugs. 
Quantification of drugs was undertaken with non-chiral SPE-UPLC-MS/MS method. Both methods are 
outlined below and described in detail elsewhere (3, 13).  
2.3.1. The verification of enantiomeric fractions of chiral drugs with SPE-Chiral LC-MS/MS  
Chiral drugs were extracted from filtered wastewater (100 mL) and surface water (500 mL) using SPE 
Gilson ASPEC XL4 (Anachem, UK) and Oasis HLB adsorbents (Waters, UK). All samples were 
filtered, adjusted to pH 7.5 with NaOH and then spiked with 100 ng of each internal standard. Analytes 
were eluted from HLB cartridge with 4 mL of MeOH. The extracts were evaporated to dryness with 
TurboVap evaporator (Caliper, UK, 40
o
C, N2, 5-15 psi) and finally reconstituted in 0.5 mL of mobile 
phase.  
Waters ACQUITY UPLC
TM
 system (Waters, Manchester, UK) equipped with Chiral-CBH column, 
100x2mm, 5µm (Chromtech, Congleton, UK) and Chiral-CBH 10x2.0mm guard column (Chromtech, 
Congleton, UK) were used for the analysis of enantiomers of chiral drugs. The separation of chiral drugs 
was undertaken at 25
o
C, under isocratic conditions and with the usage of mobile phase (pH, 5.0; flow 
rate, 0.075 mL/min) composed of 90% H2O, 10% 2-propanol and 1 mM ammonium acetate. An 
injection volume of 20 µL was used. 
A TQD (triple quadrupole) mass spectrometer (Waters, Manchester, UK), equipped with an electrospray 
ionisation source was used for the quantification of drugs of abuse. The analyses were performed in 
positive mode. MassLynx 4.1 (Waters, UK) software was used to collect and analyse the obtained data. 
Mass spectrometry analyses were performed in the multiple reaction monitoring mode(Tab. S3). All 
method validation parameters and sample mass chromatograms are presented in Tab. S4, Fig. S2 and 
S3.  
The relative concentration of enantiomers of chiral drugs was expressed as the enantiomeric fraction 
(EF) and was calculated with the following equation:  
2E1E
E1
FE

            
where E1 and E2 are peak areas for the first (E1) and the last (E2) enantiomer of a chiral drug eluting 
from the CBH column (Fig. S2). EF equals 1 or 0 in the case of single enantiomer form and 0.5 in the 
case of racemate. In the case of amphetamine, methamphetamine, MDMA and MDA, E1 and E2-
enantiomers were identified as R(-) and S(+)-enantiomers respectively. In the case of ephedrine, E1 and 
E2 denoted 1R,2S(-)-ephedrine and 1S,2R(+)-ephedrine respectively. In the case of atenolol, E1 and E2 
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denoted R(+) and S(-)-atenolol respectively. Enantiomers of amphetamine, methamphetamine and 
ephedrine were confirmed in this research through the usage of enantiomerically pure standards. 
Identification of elution order of MDMA, MDA and atenolol was based on data published by others (14, 
15, 16). EFs were calculated for all detected drugs with S/N ratios >10. 
Ephedrine/pseudoephedrine has two chiral centres and as a result two pairs of enantiomers. The 
ephedrine enantiomers have a diastereomeric relationship with pseudoephedrine enantiomers. 
Therefore, for 1R,2S(-)-ephedrine and 1S,2S(+)-pseudoephedrine diastereomeric fractions (DF) were 
also calculated: 
drinepseudoephe-)S,2S(ephedrine-1R,2S(-)
ephedrine-1R,2S(-)
DF


1
     
     
2.3.2. Quantification of chiral drugs with SPE-UPLC-MS/MS  
Solid phase extraction of samples was carried out as described above. Oasis MCX cartridge was used 
for the extraction of all analytes. 500 mL of acidified river water and 100 mL of wastewater were spiked 
with 50 ng of each surrogate/internal standard and then passed through the MCX cartridge. Cartridges 
were washed with 0.6%HCOOH/MeOH (2 mL, pH 2) followed by elution with 7%NH4OH/MeOH (3 
mL) into silanised vials. Extracts were evaporated to dryness (40 °C, N2, 2-10 psi) and reconstituted 
with 0.3%CH3COOH/5%MeOH/H2O (0.5 mL).   
Analyses were carried out with the usage of Waters ACQUITY UPLC
TM
 system (Waters, UK) and 
ACQUITY UPLC BEH C18, 150x1mm, 1.7µm column (Waters, UK). The UPLC method employed 
mobile phase A (pH 2.9): 79.7%H2O, 20%MeOH, 0.3%CH3COOH and mobile phase B (pH 3.30): 
99.7%MeOH, 0.3%CH3COOH at a flow rate of 0.04 mL min
-1 
and a temperature of 30 °C. The gradient 
programme was as follows: 0min-100%A, 17min-41.3%A, 17.2min-0%A, 20.2min-0%A, 20.3min-
100%A, 34.0min-100%A. An injection volume of 20 µL was used. 
A triple quadrupole mass spectrometer (TQD, Waters, UK) was used as described above. All method 
validation parameters were determined and are presented in Tabs. S3 and S5. 
3. Results and discussion 
3.1. MDMA and MDA 
Both MDMA and MDA, which are ring-substituted amphetamine analogues, are characterised by one 
asymmetric carbon centre and exist in the form of two enantiomers. The pharmacological actions of 
both the MDMA and MDA enantiomers differ both quantitatively and qualitatively. S(+)-enantiomers 
are thought to be more amphetamine-like stimulants and R(-)-enantiomers are more hallucinogenic (17). 
MDMA is a selective serotonin (5-HT) neurotoxin. The S(+)-isomer of MDMA has been reported to be 
a more potent neurotoxin than the R(-)-isomer. Unlike MDMA, however, both isomers of MDA cause 
long-term serotonin neurotoxicity (18). In fact, much of the neurotoxicity originally attributed to 
MDMA may actually be a result of its more potent neurotoxic metabolite, MDA (19). 
MDMA does not currently have medical applications and its clandestine manufacture (e.g. reductive 
amination or the Leuckart method) leads to the production of racemic MDMA (20). It is however 
known to undergo stereoselective metabolism in humans and animals with preferential metabolism of 
S(+)-MDMA, which leads to enrichment of MDMA with R(-)-enantiomer and formation of S(+)-MDA. 
Moore et al. (18) observed that both primary routes of excretion in human (bile and urine) had greater 
concentrations of R(-)-MDMA than the S(+) isomer (EF of 0.57, autopsy findings). These fluids also 
contained twice the concentration of S(+)-MDA than the R(-)-isomer (EF=0.37, autopsy findings) (18). 
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MDMA was indeed found in this study, in raw wastewater samples, to be enriched with R(-)-MDMA. 
Its concentrations varied from <LOQ to 455 ng/L in raw wastewater and from <LOQ to 115 ng/L in 
treated wastewater. This high variability in concentrations of MDMA might be due to both different 
patterns of usage as well as the influence of dry/wet weather conditions. Mean EFs values for raw and 
treated wastewater collected during 5 sampling campaigns and at 7 different WWTPs were found to be 
0.68 and 0.78 respectively (Fig. 1, Fig. S4 and Tab. S6). This indicates further enrichment of MDMA 
with R(-)-enantiomer as a result of wastewater treatment, probably due to enantioselective microbial 
activity. Over the course of the sampling campaign the change of EFs of MDMA as a result of 
wastewater treatment varied from -11 to 73.6%. The highest stereoselectivity of the transformation of 
MDMA was observed in WWTPs 5, 6 and 7, which is where activated sludge processes are 
implemented. For example, in the August sampling campaign EFs values increased from 0.63±0.02 
0.72±0.07 and 0.64±0.01 in raw wastewater to 0.84±0.01, 0.91±0.00 and 0.78±0.01 in treated 
wastewater in WWTPs 5, 6 and 7 respectively. During the same sampling campaign, EFs of MDMA 
increased only slightly from 0.64±0.00 and 0.68±0.02 in raw wastewater to 0.69±0.00 in treated 
wastewater in WWTPs 2 and 3 respectively. This is an important observation indicating that different 
consortia of microorganisms, which are utilized in both activated sludge (WWTPs 4-7) and trickling 
filter bed treatment (WWTPs 1-3), can show different stereoselectivity. 
MDMA was also quantified in receiving waters at low ppt levels not exceeding 20 ng/L (2.3 g/day) 
(Fig. 1, Tab. S6). Change in EFs (enrichment of MDMA with R(-) enantiomer) was observed with the 
course of the river, which might be due to microbial processes occurring or as a result of a discharge of 
non-racemic MDMA with treated wastewater effluent. This process was found to be more prominent in 
April and August, when microbial activity is higher than during winter times, thus suggesting 
stereoselective microbial processes occurring. For example, during the August sampling campaign EF 
of MDMA denoted only 0.56±0.01 in sampling point located before WWTP 1 (see Fig. S1 for sampling 
points locations) and increased to 0.80±0.01 in sampling point located after WWTP 6 over 50 km 
downstream from sampling point 1. It has to be however noted that the change of EF of MDMA 
throughout the course of the river can also be affected by a discharge of non-racemic MDMA to the 
river from WWTPs 1-6. 
MDA is a demethylated metabolite of MDMA and is also available on the illicit market. It is 
synthesized (similarly to MDMA) in racemic form. It is also known that (similarly to MDMA) S(+)-
MDA is preferentially metabolized leading to enrichment of excreted MDA with R(-)-enantiomer (21). 
However, if the presence of MDA in urine is expected due to MDMA abuse and not direct MDA use, an 
enrichment of MDA with S(+)-enantiomer should be anticipated in urine and subsequently in 
wastewater. Almost twice as much S(+)-MDA is excreted in urine as compared to R(-)-MDA (19). This 
was also the case in the discussed study. MDA was only quantified in the August sampling campaign (at 
concentrations not exceeding 50 ng/L and 20 ng/L in the case of raw and treated wastewater 
respectively, see Fig. 2) and it was found in raw wastewater to be enriched with S(+)-enantiomer (EF = 
0.26±0.04 and 0.30±0.03 in the case of WWTP 2 and 3), which suggests that its presence might be 
associated with MDMA abuse and not intentional MDA use. Interestingly, an enrichment of MDA with 
R(-)-enantiomer (ranging from 23 to 45%) was observed during wastewater treatment (EF = 0.38±0.03 
and 0.40±0.01 in the case of WWTP 2 and 3 effluents respectively), which suggests stereoselective 
processes occurring (Fig. 2, Tab. S7). MDA was also quantified in receiving waters at concentrations 
not exceeding 5 ng/L (0.1g/day) (Fig. 2, Tab. S7). EFs recorded in surface water were higher than those 
observed in WWTP 2 and 3 but in line with EFs recorded in WWTP1 and ranged from 0.56±0.02 to 
0.58±0.08. This again might indicate that preferential removal or transformation of S(+)-enantiomer in 
water takes place leading to enrichment of MDA with R(-)-enantiomer. 
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3.2. Amphetamine and methamphetamine 
Amphetamine, similarly to MDMA, contains one asymmetric carbon and as a result can exist in the 
form of two enantiomers, which significantly differ in potency:  S(+)-amphetamine has twice as high 
stimulant activity than R(-)-amphetamine (3). The most common route of clandestine synthesis of 
amphetamine is the Leuckart method which yields a racemic amphetamine (20). Furthermore, both 
S(+)- and S(+)-/R(-)-amphetamine are prescription medications and have medical applications. 
Amphetamine is used in narcolepsy, attention deficit disorder in children and short term weight loss 
(22). According to NHS statistics (23) in England, only S(+)-amphetamine is prescribed 
(dexamfetamine and lisdexamphetamine: 25 and 0.01 kg/2010). These are relatively low levels when 
compared to illegal use (estimated usage of amphetamine and methamphetamine: 4.0 tonnes in 
2003/2004; calculated with reference to seizures, purity and survey-based estimates of usage) (32). 
Amphetamine can also be excreted in different enantiomeric forms as a result of metabolism of 
methamphetamine and certain prescription drugs (e.g. selegiline, prescription in England: 13 kg/2010 
(23), which leads to the metabolic formation of R(-)-amphetamine and R(-)-methamphetamine). 
Similarly to MDMA, S(+)-amphetamine metabolises faster than R(-)-enantiomer if administered in 
racemic form (20, 22, 24). This wide usage of different forms of amphetamine and its stereoselective 
metabolism make an understanding of enantiomer-specific fate of amphetamine in the environment 
difficult, although not impossible.  
The results of this study indicated that amphetamine in wastewater was enriched with R(-)-enantiomer. 
Recorded EFs were ranging from 0.52±0.01 to 0.84±0.01 with average value of 0.64. This was to be 
expected in raw wastewater because, as mentioned above, amphetamine is usually abused in racemic 
form with preferential metabolism of S(+)-amphetamine leading to an enrichment of excreted 
amphetamine with R(-)-enantiomer. It has to be however emphasized here that (although unlikely due to 
low usage) possible contribution to enantiomeric composition of amphetamine from legally prescribed 
S(+)-amphetamine and selegiline should be taken into account. Although based on only a few samples, 
a faster removal of S(+)-amphetamine, probably due to stereoselective microbial activity, was also 
observed during wastewater treatment (Fig. 3, Tab. S9). This led to further enrichment of amphetamine 
with R(-)-enantiomer in treated wastewater (EFs > 0.70). As an example, during April sampling 
campaign, EF of amphetamine in WWTP 3 and 4 denoted 0.65±0.00 and 0.59±0.04 respectively in raw 
wastewater and increased to 0.71±0.03 and 0.78±0.01 as a result of WWTP treatment (Tab. S9). 
Amphetamine was also quantified in receiving waters at single ng/L (<1.7 g/day) levels and was found 
to be enriched with R(-)-enantiomer at all times (EFs > 0.80; see Fig. 3 and Tab. S9).  
Psychostimulant effects of methamphetamine, similarly to amphetamine, are enantioselective, and S(+)-
enantiomer is much more active than R(-)-enantiomer. As opposed to amphetamine, S(+)-enantiomer of 
methamphetamine is the most commonly abused drug and produced in clandestine laboratories (20). 
Methamphetamine is also used for valid medical treatment as S(+)-methamphetamine (to treat attention 
deficit disorder in children, narcolepsy and exogenous obesity) (22, 24). In the USA also R(-)-
methamphetamine is used as decongestant in the Vicks Inhaler (an over-the-counter medication). 
Methamphetamine can be also formed as a result of metabolism of certain prescription medications (e.g. 
selegiline leading to the formation of R(-)-methamphetamine). Currently, there is no medical use of 
methamphetamine in England. Therefore, if present in wastewater it is thought to result from its abuse 
or metabolism of other drugs. In this study, methamphetamine was only quantified in the August 
sampling campaign and was found to be racemic in WWTP 1 influent (EF, 0.53±0.05) but enriched with 
S(+)-enantiomer in the influent of WWTPs 2 and 4 (EF, 0.22±0.00 and 0.28±0.04 respectively)  (Fig. 2, 
Tab. S8). In all WWTPs, treatment of wastewater resulted in stereoselective removal of 
methamphetamine leading, similarly to amphetamine, to an enrichment of methamphetamine with R(-)-
enantiomer (EF, 0.87±0.19, 1.00±0.00 and 0.70±0.06 in the case of WWTP 1, 2 and 4 respectively).  
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3.3. Ephedrine and pseudoephedrine 
Ephedrine has two chiral carbons and can therefore exist in the form of four stereoisomers: 1R,2S(-)-
ephedrine, 1S,2R(+)-ephedrine, 1S,2S(+)-pseudoephedrine and 1R,2R-(-)-pseudoephedrine. However, 
only two stereoisomers: 1R,2S(-)-ephedrine and 1S,2S(+)-pseudoephedrine can be found in natural 
sources such as ephedra (25). 1R,2S(-)-Ephedrine finds wide applications as a bronchodilator to treat 
bronchospasm associated with asthma, bronchitis and emphysema. It is also abused for its stimulant 
properties. 1S,2S(+)-Pseudoephedrine is used as a decongestant (20). 
Ephedrine has been detected before in environmental matrices (26, 27), but with the usage of non-
enantioselective methodology, which did not allow for enantiomeric and diastereomeric ephedrine 
profiling and as a result did not allow for an accurate assessment of possible effects ephedrine might 
have on the environment. Enantiomeric/diastereomeric profiling is of vital importance as different 
stereoisomers of ephedrine differ significantly in potency (1R,2S(-)-ephedrine has much higher 
stimulant properties than 1S,2S(+)-pseudoephedrine) and possibly also toxicity to certain organisms.  
In this study a verification of the enantiomer-specific fate of ephedrine isomers was undertaken (Fig. 4, 
Fig. S6, Tab. S10). Out of the two enantiomers of ephedrine (1S,2R(+)- and 1R,2S(-)-) only natural 
1R,2S(-)-enantiomer was frequently detected. Synthetic 1S,2R(+)-Ephedrine was detected at low levels 
in only certain WWTPs throughout the sampling campaign. It was detected on several occasions in 
WWTP 2 but only in treated wastewater (EF, 0.55±0.00, 0.22±0.00, 0.89±0.00, 0.91±0.00 during 
January, February, March and August sampling campaigns respectively), which might suggest 
stereoselective processes occurring during treatment (e.g. chiral inversion although there is currently no 
experimental evidence to support this claim) leading to enrichment of ephedrine with 1S,2R(+)-
enantiomer. The possibility of chiral inversion occurring during treatment is of critical importance in 
understanding the fate of ephedrines in the environment and has to be studied further. A similar 
situation was observed in WWTP 7 (only in the August sampling campaign: EF, 0.72±0.03 in treated 
wastewater). In WWTP 3, 4 and 6 during the August campaign 1S,2R(+)-ephedrine was detected in both 
influent and effluent wastewater (Fig. S3). A low enrichment of ephedrine with 1S,2R(+)-enantiomer 
was observed in all three WWTPs (decrease of EF from on average 0.90 to on average 0.82), which 
indicates stereoselectivity of processes occurring during treatment. For example, EF of ephedrine in 
WWTP 3, 4 and 7 denoted 0.95±0.07, 0.96±0.01 and 0.81±0.01 respectively in raw wastewater and 
decreased to 0.90±0.02, 0.83±0.05 and 0.76±0.02 as a result of WWTP treatment (Tab. S9). As a result 
of enrichment of ephedrine with 1S,2R(+)-enantiomer during wastewater treatment, 1S,2R(+)-ephedrine 
was also detected in receiving waters (Fig. 4, Tab. S10). EFs for ephedrine varied from 1.00 
(December-March) to 0.80±0.00, and were the lowest in the April and August campaign, which might 
suggest enantioselective processes occurring during spring/summer due to potentially higher activity of 
microorganisms. 
The verification of cumulative concentrations of ephedrines in raw wastewater indicated that higher 
levels of these compounds were observed during winter time (reaching 180 g/day in February in all 
studied WWTPs) than during summer time (< 80 g/day in August). Interestingly, the analysis of 
diastereomeric fractions of 1R,2S(-)-ephedrine and 1S,2S(+)-pseudoephedrine in raw wastewater 
revealed that over the winter months ephedrines were enriched with 1S,2S(+)-pseudoephedrine (Fig. 4, 
Fig. S6, Tab. S10). This is possibly due to higher usage of over-the-counter medications (containing 
1S,2S(+)-pseudoephedrine) for the treatment of mild symptoms of cold. During the spring and summer 
months a reverse situation was observed as ephedrine was found to be enriched with a much more 
potent stimulant, 1R,2S(-)-ephedrine. For example, DFs values increased from 0.09±0.00, 0.02±0.00, 
0.12±0.01, 0.25±0.01, 0.19±0.01 and 0.07±0.02 in the January sampling campaign to 0.44±0.01, 
0.56±0.01, 0.51±0.04, 0.47±0.00, 0.44±0.00 and 0.66±0.00 in the August sampling campaign WWTPs 
1, 2, 4, 5, 6 and 7 respectively. This is a very important finding indicating that non-enantioselective 
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measurement of ephedrines cannot be a reliable indicator of actual potency of ephedrines in the 
environment. Higher cumulative concentrations of ephedrines, which are enriched with less potent 
1S,2S(+)-pseudoephedrine (as was during winter time in this study) might be of lower environmental 
significance than lower concentrations of ephedrines enriched with much more potent 1R,2S(-)-
ephedrine (in summer in this study). Furthermore, wastewater treatment resulted in almost all cases in 
further enrichment of ephedrines in aqueous phase with more potent 1R,2S(-)-ephedrine, with an 
average increase of DFs from 0.25 in raw wastewater to 0.35 in treated wastewater (see Tab. S10). For 
example, in the August sampling campaign, DF of ephedrine in WWTP 1, 5 and 6 denoted 0.44±0.01, 
0.47±0.00 and 0.44±0.00 respectively in raw wastewater and increased to 0.82±0.01, 0.66±0.02 and 
0.68±0.02  as a result of WWTP treatment. Interestingly, the monitoring of receiving waters revealed 
that ephedrine was enriched with 1R,2S(-)-ephedrine at the beginning of the course of the river and its 
DFs decreased over the course of the river indicating an increase of 1S,2S(+)-pseudoephedrine (e.g. 
during the August sampling campaign DF of ephedrine denoted 0.93±0.03 in sampling point located 
before WWTP 1 and decreased to 0.33±0.03 in sampling point located after WWTP 6 over 50 km 
downstream from sampling point 1); a reverse situation to the one observed during wastewater treatment 
(Fig. 4 and Tab. S10). This might indicate that different microbial communities are responsible for 
transformation of ephedrines during wastewater treatment and in the environment.  
3.4. Venlafaxine 
Venlafaxine is an inhibitor of reuptake of both serotonin and noradrenaline and is one of the most 
frequently prescribed antidepressant drugs worldwide (England: 9 tonnes/2010 (23)). It is marketed as a 
racemate. Both of the enantiomers exhibit pharmacological activity, but interact with different signal 
molecules in the central nervous system. The R(-)-enantiomer is a potent inhibitor of both serotonin and 
noradrenaline reuptake, while the S(+)-enantiomer is more selective in inhibiting serotonin reuptake (2, 
28).  Oral clearance of venlafaxine is higher for the R(-)-enantiomer (29).  
In this study venlafaxine was found to be omnipresent in both wastewater and in receiving waters (Fig. 
5, Fig. S7 and Tab. S11). Its concentrations in raw wastewater varied from tenths to a few hundred ng/L. 
WWTP treatment did not effectively remove this compound as treated wastewater contained its 
significant concentrations, sometimes higher than in raw wastewater. This is probably due to cleavage 
of free venlafaxine from its conjugated form due to microbial processes occurring during wastewater 
treatment (although there is currently no experimental evidence to support this claim). As a result it was 
found in receiving waters at concentrations of tenths ng/L (<35 g/day). EFs of venlafaxine were on 
average 0.48 in raw sewage and were observed to slightly increase in almost all cases to on average 0.52 
in treated wastewater. For example, in the August sampling campaign, EF of venlafaxine in WWTP 1, 3 
and 7 denoted 0.46±0.02, 0.39±0.03 and 0.47±0.00 respectively in raw wastewater and increased to 
0.51±0.01, 0.52±0.00 and 0.50±0.01 as a result of WWTP treatment. This indicates some weak 
stereoselective processes occurring during wastewater treatment, although not as significant as in the 
case of other chiral drugs studied in this work (the difference in EFs, although very small, is statistically 
significant, see Tab. S11). Interestingly, in receiving waters, more significant changes of EFs of 
venlafaxine (both with the flow of the river and time of year) were observed. The lowest EF of 
0.40±0.02 indicating enrichment of venlafaxine with E2 enantiomer was observed in the December 
sampling campaign (Fig. 5, Tab. S11). The highest EF of 0.65±0.01 indicating enrichment of 
venlafaxine with E1 enantiomer was recorded in the August sampling campaign, which is when 
microbial activity is the highest. Surprisingly EFs of venlafaxine in receiving waters did not always 
correspond with EFs of venlafaxine in discharged wastewater effluent. It is also worth noting that higher 
variability in EFs of venlafaxine (usually enrichment with  E1-enantiomer) was observed in sampling 
points located further from a WWTP discharge point (see Fig. 5, Tab. S11, sampling points: ‘before 
WWTP 1, 3 and 6’) than those just after a discharge of treated wastewater. This suggests that some 
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stereoselective processes regarding venlafaxine take place in the river and are more significant than 
those observed during wastewater treatment. Despite the fact that in the discussed research distinction 
between levorotary and dextrorotary enantiomers of venlafaxine was not possible, one can observe that 
analysis of this compound at enantiomeric level provides yet another dimension to the understanding of 
its fate in the environment.  
3.5. Atenolol 
Atenolol belongs to the group of beta-blockers. It’s prescription in England exceeds 30 tonnes annually 
(2). Pharmacological action of beta-blockers in humans is highly stereoselective. S(-)-Enantiomers 
usually reveal much higher cardiac beta-blocking potency than R(+)-enantiomers in most beta-blockers, 
with an activity ratio being in the region of S : R from 33 to 530. On the other hand R(+)-enantiomers 
have higher activity in blocking β2 receptors in ciliary processes (2). Modest stereoselectivity in renal 
clearance of atenolol in humans in favour of S(-)-enantiomer results in an enrichment of excreted 
atenolol with this enantiomer (30). Indeed atenolol was found to be enriched with S(-)-enantiomer in 
both raw and treated wastewater (average EF=0.40 for raw wastewater and 0.46 in treated wastewater) 
(Fig. 6, Fig. S8, Tab. S12). These results correspond with those already published by Nikolai et al. (7) 
and MacLeod et al. (31). However, it is important to emphasize that during wastewater treatment 
enrichment of atenolol with R(+)-enantiomer took place in several cases. This outcome is contrary to the 
outcome reported by Nikolai et al. (7) and MacLeod et al. (8), where an enrichment of atenolol with S(-
)-enantiomer was observed. The highest stereoselectivity of the removal of atenolol was observed in the 
case of WWTP 4 (an increase of EF from 0.35±0.02 in raw wastewater to 0.49±0.02 (0.48±0.04) in 
treated wastewater in the March (April) sampling campaign), WWTP 6 (an increase of EF from 
0.33±0.04 (0.31±0.05) in raw wastewater to 0.49±0.01 (0.45±0.01) in treated wastewater in the March 
(April) sampling campaign) and WWTP 7 (an increase of EF from 0.33±0.03 (0.32±0.02) in raw 
wastewater to 0.61±0.00 (0.52±0.02) in treated wastewater respectively in the March (April) sampling 
campaign) where activated sludge technology is being utilized. No or low stereoselectivity was 
observed in WWTPs 1, 2 and 3 where trickling filters are used. For example during the August 
sampling campaign EFs of atenolol did not change as a result of wastewater treatment in WWTP 1, 2 
and 3 and denoted 0.44±0.01, 0.44±0.01 and 0.43±0.01 respectively. This is an important observation 
indicating the importance of a type of technology in use. In the case of activated sludge treatment 
aerobic microbial processes take place. While in the case of trickling filter bed technology anaerobic 
microbial processes also occur and these might not be stereoselective in nature. To test this hypothesis 
and verify which consortia of microorganisms might be responsible for enantiomer-specific fate of 
drugs, further research will need to be undertaken. 
In receiving waters, the lowest EF was recorded for atenolol in August (0.39±0.00) and the highest in 
March (0.56±0.09). There was also a strong tendency during the spring/summer months (April-August) 
for an enrichment of atenolol with the flow of the river with S(-)-enantiomer. It has to be remembered 
here that a reverse pattern was observed in this study during wastewater treatment processes. This 
suggests that different consortia of microorganisms and/or environmental conditions are involved in 
stereoselective degradation of atenolol in receiving waters and during wastewater treatment. 
To summarise, the phenomenon of the enantiomer-specific fate of chiral drugs such as amphetamines, 
atenolol or venlafaxine is of vital importance and needs to be taken into account in environmental risk 
assessment. This is because:  
 these drugs are distributed as racemates,  
 their enantiomers reveal different pharmacological activity (and possibly different ecotoxicity),  
 their metabolism in humans is stereoselective and as a result they are discharged into wastewater 
in non-racemic mixtures, 
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 their fate during wastewater treatment shows stereoselectivity, which depends on the type of 
technology utilised (e.g. activated sludge shows higher stereoselectivity than trickling filters in 
the case of atenolol) 
 their fate in the aqueous environment is also stereoselective and is season and location dependant 
(in certain cases observed stereoselectivity is different to the one recorded during wastewater 
treatment) 
After taking the above discussion into consideration, one can hypothesize that the environmental risk 
assessment of chiral pharmacologically active compounds, which currently does not take into account 
their enantiomer-specific fate, might significantly under- (or over-) estimate their actual impact on the 
surrounding environment.  
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Figure 1. Concentrations and enantiomeric fractions of MDMA in WWTPs and receiving waters (note: 
different methods were used for quantification of drugs and enantiomeric profiling; see Tabs. S4 and S5 
for validation parameters). 
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Figure 2. Concentrations and enantiomeric fractions of MDA and methamphetamine in WWTPs and 
receiving waters (note: different methods were used for quantification of drugs and enantiomeric 
profiling; see Tabs. S4 and S5 for validation parameters). 
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Figure 3. Concentrations and enantiomeric fractions of amphetamine in WWTPs and receiving waters 
(note: different methods were used for quantification of drugs and enantiomeric profiling - see Tabs. S4 
and S5 for validation parameters. Due to high variability of MS ion ratios in the case of amphetamine 
quantitation results should be considered on semi-quantitative basis). 
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Figure 4. Concentrations and enantiomeric/diastereomeric fractions of ephedrine in WWTPs and 
receiving waters (note: different methods were used for quantification of drugs and enantiomeric 
profiling; see Tabs. S4 and S5 for validation parameters) 
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Figure 5. Concentrations and enantiomeric fractions of venlafaxine in WWTPs and receiving waters 
(note: different methods were used for quantification of drugs and enantiomeric profiling; see Tabs. S4 
and S5 for validation parameters). 
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Figure 6. Concentrations and enantiomeric fractions of atenolol in WWTPs and receiving waters 
(note:  chiral-LC-MS/MS method was used for both quantification of drugs and enantiomeric profiling; 
see Tab. S4 for validation parameters). 
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Table S1. Chemical formulas, molecular weights and CAS numbers of selected chiral drugs. 
Name CAS MW Structure 
R/S-(±)-Amphetamine 
C9H13N 
R(-): 300-62-9 
S(+): 51-64-9 
R/S-(±): 300-62-9                                                                                         
135.2 CH3
NH2
*
 
R/S-(±)-Methamphetamine 
C10H15N 
R(-): 33817-09-3 
S(+): 537-46-2 
149.2 CH3
NH
CH3
*
 
R/S-(±)-MDA 
C10H13NO2 
4764-17-4 179.2 CH3
NH2
O
O
*
 
R/S-(±)-MDMA 
C11H15NO2 
42542-10-9 193.2 CH3
NH
O
O CH3
*
 
1R,2S-(-)-Ephedrine HCl 
C10H15NO·HCl 
50-98-6 201.7 
CH3
NH
CH3
OH
*
*
 
1S,2R-(+)-Ephedrine HCl 
C10H15NO·HCl 
24221-86-1 201.7 
1S,2S-(+)-Pseudoephedrine HCl 
C10H15NO·HCl 
345-78-8 201.7 
1R,2R-(-)-Pseudoephedrine 
C10H15NO 
90-82-4 165.2 
R/S-(±)-Venlafaxine HCl 
C17H27NO2·HCl 
99300-78-4 313.9 
OH
O
CH3
N
CH3
CH3
*
 
R/S-(±)-Atenolol 
C14H22N2O3 
29122-68-7 266.3 NH2
O
NH
OH
O
*
 
                                                 
*
Corresponding author: E-mail: b.kasprzyk-hordern@bath.ac.uk; Fax: +44(0) 1225 386231; Tel: +44 (0) 
1225 385013 
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R/S-(±)-Amphetamine-d11 
C9H2D11N 
NA 146.3 D
C
D
D
D
D
D
D
CD3
NH2
D
*
 
R/S-(±)-Methamphetamine-d14 
C10HD14N 
NA 163.1 D
C
D
D
D
D
D
D
CD3
NH
D
CD3*
 
R/S-(±)-MDA-d5 
C10H8D5NO2 
136765-42-9 184.2 
NH2
CD3O
O
D
H D
*
 
R/S-(±)-MDMA-d5 
C11H10D5NO2 
136765-43-0 198.2 
NH
CH3O
O CD3
D
H D
*
 
*- chiral centre 
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Figure S1. Location of WWTPs and river sampling points.  
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Table S2. General information on the studied WWTPs and receiving waters. 
WWTP Parameter 
Population 
served 
(thousands) 
Flows  
[L s
-1
] 
Wastewater  
(% industrial/ 
%domestic) 
Treatment technology Receiving 
waters 
Dilution 
factor 
WWTP 1 15 89-212 10-15/85-90 Trickling filter beds - 
WWTP 2 10 32-75 10-15/85-90 Trickling filter beds - 
WWTP 3 11 40-115 10-15/85-90 Trickling filter beds 16-27 
WWTP 4 190 366-1300 30/70 Activated sludge - 
WWTP 5 240 603-1231 30/70 30% BAFF, 15% 
trickling filter beds, 
55% activated sludge 
- 
WWTP 6 244 476-1378 30/70 75% activated sludge, 
25% trickling filter 
beds 
9-20 
WWTP 7 190 395-563 20/80 Activated sludge - 
 
 
Table S3. Optimised MRM conditions for the analysis of chiral drugs by UPLC/MS/MS (CV-cone 
voltage [V]; CE-collision energy [eV]). 
Analyte CV/CE MRM1 
(quantification) 
CV/CE MRM2 
(confirmation) 
R/S(±)-Amphetamine 18/8 136.16>119.10 18/16 136.16>91.10 
1R,2S(-)/1S,2R(+)-Ephedrine/           
1S,2S(+)/1R,2R(-)-Pseudoephedrine 
23/12 166.09>148.10 23/21 166.09>133.00 
R/S(±)-MDA 21/11 180.03>163.10 21/22 180.03>105.10 
R/S(±)-MDMA 24/13 194.09>163.10 24/24 194.09>105.10 
R/S(±)-Methamphetamine 24/10 150.20>119.05 24/19 150.20>91.10 
R/S(±)-Venlafaxine 27/12 278.15>260.10 27/32 278.15>121.00 
R/S(±)-Atenolol 34/19 266.9>190.10 34/25 266.9>145.00 
R/S(±)-Amphetamine-d11 18/8 147.16>130.10 - - 
R/S(±)-MDA-d5 21/11 185.09>168.10 - - 
R/S(±)-MDMA-d5 26/13 199.1>165.10 - - 
R/S(±)-Methamphetamine-d14 24/19 164.16>98.10 - - 
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Table S4. Validation parameters for SPE-Chiral LC-MS/MS method. 
Analyte Method parameters
 
EFo* 
 
Rs**
 
R
2
*** RSD% 
(n=3) 
MQL**** [ng/L] 
10 
[ng/L] 
50 
[ng/L] 
WWTP 
influent 
WWTP 
effluent 
River 
R/S(±)-Amphetamine 
(IS: R/S-(±)-AMPH-d11) 
0.52±0.02 2.1 0.999 6.5 3.7 - - - 
1R,2S(-)-Ephedrine 
(IS: R/S-(±)-MDMA-d5) 
0.52±0.03***** 1.2 0.998 3.6 5.2 - - - 
1S,2S(+)-Pseudoephedrine 
(IS: R/S-(±)-MDMA-d5) 
2.3 0.999 8.7 6.8 - - - 
R/S(±)-MDA 
(IS: R/S-(±)-MDA-d5) 
0.48±0.01 3.0 0.998 7.8 3.3 - - - 
R/S(±)-MDMA 
(IS: R/S-(±)-MDMA-d5) 
0.48±0.01 1.9 0.999 7.5 2.6 - - - 
R/S(±)-
Methamphetamine 
(IS: R/S-(±)-METH-d14) 
0.47±0.01 0.95 0.999 4.9 3.7 - - - 
E1/E2(±)-Venlafaxine 
(IS: R/S-(±)-MDMA-d5) 
0.49±0.01 0.95 0.997 4.9 4.7 - - - 
R/S(±)-Atenolol 
(IS: R/S-(±)-MDMA-d5) 
0.48±0.03 8.0 0.996 - - 1.7 1.7 0.3 
* - EFo – enantiomeric fraction in standard solution spiked with racemic chiral drug  
(concentrations: 1-500 ng/L) 
** - Rs – resolution 
***- Studied linearity range: 1-500ng/L 
****- MQL – method quantification limit 
***** the value refers to DF (diastereomeric fraction) in standard solution spiked with 1R,2S(-)-
ephedrine and 1S,2S(+)-pseudoephedrine 
IS – Internal standard 
Note: Deuterated ISs were not available for ephedrine, pseudoephedrine, venlafaxine and atenolol. For 
these compounds quantitation results should be considered on semi-quantitative basis. 
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Table S5. Validation parameters for SPE-UPLC-MS/MS method. 
Analyte Method parameters
 
Linearity 
range 
[ng/L] 
R
2 
RSD% MQL [ng/L] 
0.5 [ng/L] 50 [ng/L] WWTP 
influent 
WWTP 
effluent 
River 
Amphetamine 
(IS: Amphetamine-d11) 
0.5-1000 0.999 <MQL* 10 5.1 2.1 1.0 
Ephedrine/ Pseudoephedrine 
(IS: Amphetamine-d11) 
0.5-1000 0.999 <MQL 10.7 5.6 5.2 10 
MDA 
(IS: MDA-d5) 
0.1-1000 0.999 11 2.1 4.2 4.2 0.5 
MDMA 
(IS: MDMA-d5) 
0.1-1000 0.999 9.4 3.9 0.7 0.7 0.5 
Methamphetamine 
(IS: Methamphetamine-d14) 
0.05-1000 0.999 8.3 4.1 0.6 0.6 0.1 
Venlafaxine 
(IS: Fentanyl-d5) 
0.1-250 0.999 9.6 3.8 3.5 3.6 0.5 
* - MQL – method quantification limit 
IS – Internal standard 
Note: Deuterated ISs were not available for ephedrine, pseudoephedrine, venlafaxine and atenolol. For 
these compounds quantitation results should be considered on semi-quantitative basis. 
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Figure S2. LC-MS/MS chromatograms of chiral drugs in wastewater influent collected from WWTP 2 
during August sampling campaign.  
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Figure S3. LC-MS/MS chromatograms of chiral drugs in wastewater influent and effluent collected 
from WWTP 3 during August sampling campaign (peak 1 – 1S,2R(+)-ephedrine; peak 2 -1R,2S(-)-
ephedrine and peak 3 – 1S,2S(+)-pseudoephedrine).  
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Table S6. Concentrations and enantiomeric fractions of MDMA in WWTPs and receiving waters (Note: different methods were used for quantification of drugs 
and enantiomeric profiling; see Tabs. S4 and S5 for validation parameters; concentrations and enantiomeric fractions represent mean values for duplicate 
samples, each analyzed three times). 
WWTPs Concentration [ng/L] 
JANUARY FEBRUARY MARCH APRIL AUGUST 
WWTP 1 INFL <MQL 72.1 ± 3.0 39.8 ± 0.4 15.2 ± 0.1 76.7 ± 3.3 
  EFFL <MQL 43.9 ± 0.2 30.8 ± 1.3 29.7 ± 0.3 115.4 ± 2.1 
WWTP 2 INFL <MQL 180.1 ± 11.6 92.6 ± 4.7 91.0 ± 1.0 455.4 ± 12.3 
  EFFL <MQL 65.3 ± 8.0 79.2 ± 4.8 22.0 ± 0.1 103.1 ± 0.8 
WWTP 3 INFL <MQL <MQL <MQL 2.0 ± 0.4 42.9 ± 1.6 
  EFFL <MQL <MQL <MQL 1.9 ± 0.1 53.7 ± 1.8 
WWTP 4 INFL 2.5 ± 0.2 1.6 ± 0.3 5.4 ± 0.4 31.2 ± 0.5 19.9 ± 1.6 
  EFFL <MQL <MQL <MQL 3.7 ± 0.2 12.9 ± 0.7 
WWTP 5 INFL <MQL <MQL <MQL 1.5 ± 0.0 5.7 ± 0.2 
  EFFL <MQL <MQL <MQL 1.0 ± 0.0 8.8 ± 0.0 
WWTP 6 INFL <MQL <MQL <MQL 2.5 ± 2.1 3.0 ± 0.0 
  EFFL <MQL <MQL <MQL 1.8 ± 0.4 5.5 ± 0.0 
WWTP 7 INFL <MQL <MQL 4.3 ± 0.7 2.5 ± 0.0 25.4 ± 13.8 
  EFFL <MQL <MQL <MQL 2.3 ± 0.3 18.0 ± 0.1 
 
 
WWTPs Enantiomeric Fraction 
JANUARY FEBRUARY MARCH APRIL AUGUST 
WWTP 1 INFL 0.61 ± 0.01 0.67 ± 0.02 0.58 ± 0.01 0.69 ± 0.01 0.74 ± 0.00 
  EFFL 0.68 ± 0.01 0.71 ± 0.03 0.64 ± 0.02 0.68 ± 0.02 0.65 ± 0.00 
WWTP 2 INFL 0.64 ± 0.05 0.66 ± 0.00 0.80 ± 0.02 0.61 ± 0.01 0.64 ± 0.00 
  EFFL 0.69 ± 0.00 0.69 ± 0.00 0.71 ± 0.00 0.71 ± 0.02 0.69 ± 0.00 
WWTP 3 INFL 0.76 ± 0.01 0.65 ± 0.02 0.56 ± 0.06 0.63 ± 0.04 0.68 ± 0.02 
  EFFL 0.74 ± 0.01 0.73 ± 0.01 0.77 ± 0.00 0.71 ± 0.05 0.69 ± 0.00 
WWTP 4 INFL 0.58 ± 0.01 0.80 ± 0.02 0.52 ± 0.03 0.75 ± 0.02 0.69 ± 0.02 
  EFFL 0.73 ± 0.01 0.75 ± 0.03 0.69 ± 0.02 0.81 ± 0.01 0.75 ± 0.00 
WWTP 5 INFL 0.63 ± 0.12 - - - 0.63 ± 0.02 
  EFFL - - - - 0.84 ± 0.01 
WWTP 6 INFL 0.50 ± 0.02 - 0.63 ± 0.03 0.61 ± 0.03 0.72 ± 0.07 
  EFFL 0.75 ± 0.03 - 0.88 ± 0.00 0.82 ± 0.02 0.91 ± 0.00 
WWTP 7 INFL 0.75 ± 0.02 - 0.52 ± 0.04 0.77 ± 0.02 0.64 ± 0.01 
  EFFL 0.85 ± 0.00 - 0.91 ± 0.01 0.83 ± 0.05 0.78 ± 0.01 
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River Concentration [ng/L] 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 <MQL <MQL <MQL <MQL <MQL 0.6 ± 0.0 
After WWTP 1 <MQL <MQL 5.8 ± 0.6 2.8 ± 0.1 5.0 ± 0.2 16.3 ± 0.2 
Before WWTP 3 <MQL <MQL 1.8 ± 0.1 <MQL 1.9 ± 0.3 7.4 ± 0.3 
After WWTP 3 <MQL <MQL 2.0 ± 0.1 <MQL 1.9 ± 0.3 5.4 ± 0.2 
Before WWTP 6 <MQL <MQL <MQL <MQL 0.7 ± 0.1 4.1 ± 0.1 
After WWTP 6 <MQL <MQL <MQL <MQL 0.6 ± 0.0 4.6 ± 0.1 
 
River Loads [g/day] 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 - - - - - 
- 
- 
- After WWTP 1 - - - - 
Before WWTP 3 <MQL <MQL 0.2 ± 0.0 <MQL 0.2 ± 0.0 0.5 ± 0.0 
After WWTP 3 <MQL <MQL 2.3 ± 0.0 <MQL 0.3 ± 0.0 0.4 ± 0.0 
Before WWTP 6 <MQL <MQL <MQL <MQL 0.5 ± 0.1 1.6 ± 0.0 
After WWTP 6 <MQL <MQL <MQL <MQL 0.3 ± 0.0 2.1 ± 0.0 
 
River Enantiomeric fraction 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 - - 0.58 ± 0.02 - 0.62 ± 0.04 0.56 ± 0.01 
After WWTP 1 - - 0.68 ± 0.01 0.65 ± 0.10 0.69 ± 0.00 0.65 ± 0.00 
Before WWTP 3 0.68 ± 0.05 - 0.67 ± 0.01 0.67 ± 0.03 0.67 ± 0.03 0.62 ± 0.01 
After WWTP 3 0.63 ± 0.02 - 0.67 ± 0.00 0.67 ± 0.00 0.65 ± 0.00 0.61 ± 0.00 
Before WWTP 6 - - 0.72 ± 0.07 0.75 ± 0.00 0.81 ± 0.03 0.79 ± 0.01 
After WWTP 6 - - 0.72 ± 0.01 0.76 ± 0.00 0.80 ± 0.03 0.80 ± 0.01 
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Table S7. Concentrations and enantiomeric fractions of MDA in WWTPs and receiving waters (Note: different methods were used for quantification of drugs 
and enantiomeric profiling; see Tabs. S4 and S5 for validation parameters; concentrations and enantiomeric fractions represent mean values for duplicate 
samples, each analyzed three times). 
 
 
WWTPs Concentration [ng/L] 
AUGUST 
WWTP 1 INFL 13.8 ± 1.1 
  EFFL 17.0 ± 0.7 
WWTP 2 INFL 45.8 ± 3.8 
  EFFL 19.7 ± 0.3 
WWTP 3 INFL 11.8 ± 1.8 
  EFFL 12.3 ± 0.4 
 
WWTPs Enantiomeric fraction 
AUGUST 
WWTP 1 INFL 0.47 ± 0.04 
  EFFL 0.58 ± 0.02 
WWTP 2 INFL 0.26 ± 0.04 
  EFFL 0.38 ± 0.03 
WWTP 3 INFL 0.30 ± 0.03 
  EFFL 0.40 ± 0.01 
 
 
 
River Concentration [ng/L] 
AUGUST 
Before WWTP 1 <MQL 
After WWTP 1 3.4 ± 0.3 
Before WWTP 3 2.1 ± 0.1 
After WWTP 3 1.9 ± 0.0 
Before WWTP 6 <MQL 
After WWTP 6 <MQL 
 
River Enantiomeric fraction 
AUGUST 
Before WWTP 1 - 
After WWTP 1 0.56 ± 0.02 
Before WWTP 3 0.58 ± 0.08 
After WWTP 3 0.57 ± 0.02 
Before WWTP 6 - 
After WWTP 6 - 
 
 
River Load [g/day] 
AUGUST 
Before WWTP 1 - 
After WWTP 1 - 
Before WWTP 3 0.1 ± 0.0 
After WWTP 3 0.1 ± 0.0 
Before WWTP 6 <MQL 
After WWTP 6 <MQL 
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Table S8. Concentrations and enantiomeric fractions of methamphetamine in WWTPs (Note: different methods were used for quantification of drugs and 
enantiomeric profiling; see Tabs. S4 and S5 for validation parameters; concentrations and enantiomeric fractions represent mean values for duplicate samples, 
each analyzed three times). 
 
 
WWTPs Concentration [ng/L] 
AUGUST 
WWTP 1 INFL 0.9 ± 0.1 
  EFFL <MQL 
WWTP 2 INFL <MQL 
  EFFL <MQL 
WWTP 4 INFL 1.8 ± 0.0 
  EFFL <MQL 
 
WWTPs Enantiomeric fraction 
AUGUST 
WWTP 1 INFL 0.53 ± 0.05 
  EFFL 0.87 ± 0.19 
WWTP 2 INFL 0.22 ± 0.00 
  EFFL 1.00 ± 0.00 
WWTP 4 INFL 0.28 ± 0.04 
  EFFL 0.70 ± 0.06 
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Table S9. Concentrations and enantiomeric fractions of amphetamine in WWTPs and receiving waters (Note: different methods were used for quantification of 
drugs and enantiomeric profiling - see Tabs. S4 and S5 for validation parameters. Due to high variability of MS ion ratios in the case of amphetamine quantitation 
results should be considered on semi-quantitative basis; concentrations and enantiomeric fractions represent mean values for duplicate samples, each analyzed three times). 
WWTPs Concentration [ng/L] 
JANUARY FEBRUARY MARCH APRIL AUGUST 
WWTP 1 INFL 101.2 ± 2.5 263.3 ± 13.0 195.4 ± 13.2 1091.8 ± 103.6 332.2 ± 18.4 
  EFFL <MQL <MQL <MQL <MQL 19.7 ± 1.5 
WWTP 2 INFL 3.5 ± 1.3 80.5 ± 8.7 114.0 ± 7.1 50.7 ± 1.8 107.0 ± 8.3 
  EFFL <MQL <MQL <MQL <MQL <MQL 
WWTP 3 INFL <MQL <MQL <MQL 92.6 ± 0.4 79.1 ± 2.5 
  EFFL <MQL <MQL <MQL 10.4 ± 0.2 <MQL 
WWTP 4 INFL 80.3 ± 6.2 349.6 ± 44.1 360.5 ± 94.0 517.3 ± 49.9 518.3 ± 83.1 
  EFFL <MQL <MQL <MQL <MQL <MQL 
WWTP 5 INFL <MQL <MQL <MQL 187.0 ± 2.0 159.3 ± 0.2 
  EFFL <MQL <MQL <MQL 5.9 ± 0.2 <MQL 
WWTP 6 INFL 102.5 ± 17.0 120.0 ± 60.2 60.2 ± 13.2 317.0 ± 27.1 501.8 ± 20.9 
  EFFL <MQL <MQL <MQL <MQL <MQL 
WWTP 7 INFL 3112.5 ± 2047.1 <MQL 121.9 ± 13.5 824.7 ± 83.3 391.8 ± 1.0 
  EFFL <MQL <MQL <MQL <MQL <MQL 
 
WWTPs Enantiomeric fraction 
JANUARY FEBRUARY MARCH APRIL AUGUST 
WWTP 1 INFL 0.65 ± 0.00 - 0.67 ± 0.02 0.69 ± 0.00 0.67 ± 0.03 
  EFFL - - - - 0.84 ± 0.01 
WWTP 2 INFL 0.62 ± 0.00 0.70 ± 0.00 0.67 ± 0.05 0.69 ± 0.04 0.60 ± 0.03 
  EFFL - - - - - 
WWTP 3 INFL 0.68 ± 0.02 0.66 ± 0.01 0.70 ± 0.01 0.65 ± 0.00 0.64 ± 0.02 
  EFFL - 0.77 ± 0.02 0.77 ± 0.03 0.71 ± 0.03 - 
WWTP 4 INFL 0.71 ± 0.02 0.52 ± 0.01 0.59 ± 0.02 0.59 ± 0.04 0.59 ± 0.04 
  EFFL - - - 0.78 ± 0.01 0.68 ± 0.04 
WWTP 5 INFL 0.63 ± 0.00 0.70 ± 0.00 - 0.84 ± 0.01 0.59 ± 0.04 
  EFFL - - - 1.00 ± 0.00 - 
WWTP 6 INFL 0.56 ± 0.02 - 0.57 ± 0.00 0.58 ± 0.00 0.59 ± 0.01 
  EFFL - - 0.70 ± 0.04 0.75 ± 0.02 - 
WWTP 7 INFL 0.69 ± 0.00 - 0.58 ± 0.04 0.57 ± 0.01 0.59 ± 0.01 
  EFFL - - - - - 
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River Concentration [ng/L] 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 <MQL <MQL <MQL <MQL <MQL 2.6 ± 0.1 
After WWTP 1 <MQL <MQL <MQL <MQL <MQL 4.3 ± 0.0 
Before WWTP 3 <MQL <MQL <MQL <MQL <MQL <MQL 
After WWTP 3 <MQL <MQL <MQL <MQL <MQL <MQL 
Before WWTP 6 <MQL <MQL <MQL <MQL 1.7 ± 0.1 <MQL 
After WWTP 6 <MQL <MQL <MQL <MQL 2.0 ± 2.0 <MQL 
 
River Load [g/day] 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 - - - - - - 
After WWTP 1 - - - - - - 
Before WWTP 3 <MQL <MQL <MQL <MQL <MQL <MQL 
After WWTP 3 <MQL <MQL <MQL <MQL <MQL <MQL 
Before WWTP 6 <MQL <MQL <MQL <MQL 1.3 ± 0.0 <MQL 
After WWTP 6 <MQL <MQL <MQL <MQL 1.7 ± 1.7 <MQL 
 
River Enantiomeric fraction 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 - - - - - 0.86 ± 0.01 
After WWTP 1 - - - - - 0.81 ± 0.01 
Before WWTP 3 - - - - - - 
After WWTP 3 - - - - - - 
Before WWTP 6 - - - - - - 
After WWTP 6 - - - - - - 
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Table S10. Concentrations and enantiomeric/diastereomeric fractions of ephedrine in WWTPs and receiving waters (Note: different methods were used for 
quantification of drugs and enantiomeric profiling; see Tabs. S4 and S5 for validation parameters; concentrations and enantiomeric fractions represent mean 
values for duplicate samples, each analyzed three times). 
WWTPs Concentration [ng/L] 
JANUARY FEBRUARY MARCH APRIL AUGUST 
WWTP 1 INFL 8.7 ± 0.3 290.2 ± 50.2 139.4 ± 11.5 69.7 ± 1.0 192.0 ± 9.7 
  EFFL <MQL <MQL <MQL <MQL 15.5 ± 7.5 
WWTP 2 INFL 276.9 ± 2.5 784.7 ± 1.4 81.2 ± 7.0 295.7 ± 30.4 913.2 ± 23.1 
  EFFL <MQL <MQL <MQL 35.0 ± 0.2 <MQL 
WWTP 3 INFL <MQL 497.1 ± 32.6 215.8 ± 0.6 119.8 ± 1.5 137.6 ± 7.6 
  EFFL <MQL <MQL <MQL 61.6 ± 0.8 20.3 ± 3.8 
WWTP 4 INFL 87.4 ± 1.1 479.9 ± 25.6 451.6 ± 36.1 542.5 ± 25.2 383.8 ± 12.1 
  EFFL <MQL <MQL <MQL 25.2 ± 1.7 15.7 ± 8.4 
WWTP 5 INFL 333.9 ± 21.8 265.1 ± 12.8 1174.5 ± 74.5 176.4 ± 10.5 295.8 ± 1.2 
  EFFL <MQL <MQL 84.1 ± 21.6 <MQL <MQL 
WWTP 6 INFL 370.1 ± 2.5 712.7 ± 20.7 803.7 ± 16.3 513.7 ± 10.1 525.2 ± 12.6 
  EFFL <MQL <MQL <MQL 59.2 ± 7.2 <MQL 
WWTP 7 INFL 15171.0 ± 7678.0 1625.3 ± 15.1 785.1 ± 65.9 648.6 ± 31.2 235.3 ± 22.1 
  EFFL <MQL <MQL <MQL 5.3 ± 2.3 <MQL 
 
WWTPs Enantiomeric Fraction 
JANUARY FEBRUARY MARCH APRIL AUGUST 
WWTP 1 INFL 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 
  EFFL 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 
WWTP 2 INFL 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 
  EFFL 0.55 ± 0.00 0.22 ± 0.00 0.89 ± 0.00 1.00 ± 0.00 0.91 ± 0.01 
WWTP 3 INFL 1.00 ± 0.00 1.00 ± 0.00 - 1.00 ± 0.00 0.95 ± 0.07 
  EFFL 1.00 ± 0.00 1.00 ± 0.00 - 1.00 ± 0.00 0.90 ± 0.02 
WWTP 4 INFL 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 0.96 ± 0.01 
  EFFL 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 0.78 ± 0.00 0.83 ± 0.05 
WWTP 5 INFL 1.00 ± 0.00 1.00 ± 0.00 - 1.00 ± 0.00 1.00 ± 0.00 
  EFFL 1.00 ± 0.00 1.00 ± 0.00 - 1.00 ± 0.00 1.00 ± 0.00 
WWTP 6 INFL 1.00 ± 0.00 - 1.00 ± 0.00 1.00 ± 0.00 0.81 ± 0.01 
  EFFL 1.00 ± 0.00 - 1.00 ± 0.00 1.00 ± 0.00 0.76 ± 0.02 
WWTP 7 INFL 1.00 ± 0.00 - 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 
  EFFL 1.00 ± 0.00 - 1.00 ± 0.00 1.00 ± 0.00 0.72 ± 0.03 
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WWTPs Diastereomeric Fraction 
JANUARY FEBRUARY MARCH APRIL AUGUST 
WWTP 1 INFL 0.09 ± 0.00 0.44 ± 0.00 0.23 ± 0.01 0.08 ± 0.00 0.44 ± 0.01 
  EFFL 0.07 ± 0.05 0.10 ± 0.00 0.29 ± 0.01 0.33 ± 0.09 0.82 ± 0.00 
WWTP 2 INFL 0.02 ± 0.00 0.03 ± 0.00 0.37 ± 0.01 0.03 ± 0.00 0.56 ± 0.01 
  EFFL 0.09 ± 0.02 0.13 ± 0.13 0.53 ± 0.01 0.18 ± 0.01 0.34 ± 0.01 
WWTP 3 INFL 0.28 ± 0.05 0.07 ± 0.01 0.25 ± 0.01 0.09 ± 0.01 0.26 ± 0.04 
  EFFL 0.04 ± 0.00 0.16 ± 0.03 0.19 ± 0.00 0.22 ± 0.01 0.55 ± 0.00 
WWTP 4 INFL 0.12 ± 0.01 0.26 ± 0.01 0.16 ± 0.05 0.36 ± 0.06 0.51 ± 0.04 
  EFFL 0.21 ± 0.04 0.40 ± 0.04 0.28 ± 0.04 0.51 ± 0.00 0.47 ± 0.00 
WWTP 5 INFL 0.25 ± 0.01 0.27 ± 0.00 - 0.12 ± 0.02 0.47 ± 0.00 
  EFFL 0.60 ± 0.01 0.52 ± 0.00 - 0.30 ± 0.01 0.66 ± 0.02 
WWTP 6 INFL 0.19 ± 0.01 - 0.18 ± 0.01 0.20 ± 0.03 0.44 ± 0.00 
  EFFL 0.34 ± 0.01 - 0.35 ± 0.04 0.33 ± 0.03 0.68 ± 0.02 
WWTP 7 INFL 0.07 ± 0.02 - 0.38 ± 0.04 0.33 ± 0.04 0.66 ± 0.00 
  EFFL 0.16 ± 0.02 - 0.43 ± 0.08 0.45 ± 0.03 0.65 ± 0.06 
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River Concentration [ng/L] 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 <MQL <MQL <MQL <MQL <MQL <MQL 
After WWTP 1 <MQL <MQL <MQL <MQL <MQL <MQL 
Before WWTP 3 <MQL <MQL <MQL <MQL <MQL <MQL 
After WWTP 3 <MQL <MQL <MQL <MQL <MQL <MQL 
Before WWTP 6 <MQL <MQL <MQL 18.0 ± 1.3 8.4 ± 0.2 6.8 ± 0.1 
After WWTP 6 <MQL <MQL <MQL 19.5 ± 1.4 12.5 ± 0.6 7.7 ± 0.3 
 
River Load [g/day] 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 - - - - - - 
After WWTP 1 - - - - - - 
Before WWTP 3 <MQL <MQL <MQL <MQL <MQL <MQL 
After WWTP 3 <MQL <MQL <MQL <MQL <MQL <MQL 
Before WWTP 6 <MQL <MQL <MQL 16.1 ± 1.2 6.5 ± 0.2 2.6 ± 0.0 
After WWTP 6 <MQL <MQL <MQL 19.0 ± 1.4 10.5 ± 0.5 3.5 ± 0.1 
 
River Enantiomeric fraction 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 0.86 ± 0.00 
After WWTP 1 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 0.98 ± 0.00 
Before WWTP 3 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 0.79 ± 0.01 0.98 ± 0.00 
After WWTP 3 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 0.87 ± 0.00 0.93 ± 0.00 
Before WWTP 6 - 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 0.86 ± 0.00 
After WWTP 6 - 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 0.80 ± 0.00 
 
River Diastereomeric fraction 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 0.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 0.82 ± 0.11 1.00 ± 0.00 0.93 ± 0.03 
After WWTP 1 0.22 ± 0.01 0.59 ± 0.02 0.52 ± 0.05 0.63 ± 0.05 0.59 ± 0.06 0.85 ± 0.00 
Before WWTP 3 0.17 ± 0.00 0.50 ± 0.09 0.71 ± 0.04 0.74 ± 0.04 0.60 ± 0.03 0.89 ± 0.01 
After WWTP 3 0.00 ± 0.00 0.32 ± 0.00 0.51 ± 0.01 0.54 ± 0.03 0.61 ± 0.00 0.71 ± 0.00 
Before WWTP 6 - 0.48 ± 0.09 0.40 ± 0.11 0.28 ± 0.00 0.31 ± 0.01 0.44 ± 0.01 
After WWTP 6 - 0.35 ± 0.03 0.33 ± 0.01 0.33 ± 0.00 0.33 ± 0.05 0.33 ± 0.03 
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Table S11. Concentrations and enantiomeric fractions of venlafaxine in WWTPs and receiving waters (Note: different methods were used for quantification of 
drugs and enantiomeric profiling; see Tabs. S4 and S5 for validation parameters; concentrations and enantiomeric fractions represent mean values for duplicate 
samples, each analyzed three times).  
WWTPs Concentration [ng/L] 
JANUARY FEBRUARY MARCH APRIL AUGUST 
WWTP 1 INFL 30.0 ± 2.0 63.4 ± 3.1 28.8 ± 0.0 52.0 ± 1.7 57.6 ± 1.1 
  EFFL 25.0 ± 0.1 52.1 ± 4.1 45.0 ± 2.2 74.8 ± 0.4 71.2 ± 4.2 
WWTP 2 INFL 159.9 ± 2.0 304.5 ± 3.5 227.2 ± 5.2 286.1 ± 7.6 164.6 ± 1.7 
  EFFL 75.6 ± 1.0 117.6 ± 9.4 90.4 ± 3.1 167.4 ± 2.6 141.6 ± 1.2 
WWTP 3 INFL 29.5 ± 0.4 72.4 ± 0.6 179.3 ± 0.6 287.9 ± 8.0 187.6 ± 6.4 
  EFFL 43.1 ± 0.2 99.6 ± 3.2 101.1 ± 3.2 171.7 ± 0.1 176.1 ± 1.5 
WWTP 4 INFL 67.3 ± 0.1 104.9 ± 3.7 115.4 ± 9.9 184.9 ± 0.8 145.8 ± 7.2 
  EFFL 54.7 ± 3.2 102.1 ± 0.6 84.0 ± 3.6 142.1 ± 2.2 128.8 ± 10.7 
WWTP 5 INFL 53.9 ± 0.2 57.5 ± 2.2 62.2 ± 6.1 90.1 ± 2.1 87.7 ± 4.1 
  EFFL 46.5 ± 1.0 76.3 ± 3.3 94.9 ± 5.1 109.8 ± 6.5 93.6 ± 2.3 
WWTP 6 INFL 115.9 ± 3.4 148.8 ± 6.6 114.4 ± 6.1 178.0 ± 2.9 172.2 ± 10.7 
  EFFL 64.4 ± 4.1 100.7 ± 0.6 84.2 ± 1.6 143.2 ± 1.0 119.2 ± 1.6 
WWTP 7 INFL 115.9 ± 1.8 139.4 ± 1.8 257.2 ± 2.1 210.3 ± 2.0 325.5 ± 7.1 
  EFFL 82.0 ± 2.1 222.6 ± 11.1 135.8 ± 8.5 180.6 ± 0.2 139.7 ± 3.9 
 
WWTPs Enantiomeric Fraction 
JANUARY FEBRUARY MARCH APRIL AUGUST 
WWTP 1 INFL 0.47 ± 0.00 0.49 ± 0.01 0.47 ± 0.03 0.35 ± 0.01 0.46 ± 0.02 
  EFFL 0.47 ± 0.01 0.46 ± 0.03 0.48 ± 0.01 0.50 ± 0.00 0.51 ± 0.01 
WWTP 2 INFL 0.51 ± 0.01 0.43 ± 0.02 0.46 ± 0.00 0.42 ± 0.00 0.65 ± 0.01 
  EFFL 0.52 ± 0.01 0.52 ± 0.00 0.50 ± 0.01 0.52 ± 0.02 0.52 ± 0.01 
WWTP 3 INFL 0.47 ± 0.00 0.47 ± 0.00 0.56 ± 0.03 0.43 ± 0.00 0.39 ± 0.03 
  EFFL 0.52 ± 0.00 0.51 ± 0.01 0.51 ± 0.01 0.52 ± 0.01 0.52 ± 0.00 
WWTP 4 INFL 0.47 ± 0.01 0.43 ± 0.03 - - 0.48 ± 0.03 
  EFFL 0.51 ± 0.00 0.51 ± 0.01 0.50 ± 0.01 0.52 ± 0.01 0.51 ± 0.00 
WWTP 5 INFL 0.47 ± 0.03 0.52 ± 0.00 - 0.56 ± 0.01 0.62 ± 0.01 
  EFFL 0.58 ± 0.01 0.55 ± 0.01 - 0.56 ± 0.00 0.69 ± 0.00 
WWTP 6 INFL 0.51 ± 0.05 - 0.51 ± 0.02 0.49 ± 0.04 0.50 ± 0.00 
  EFFL 0.49 ± 0.00 - 0.51 ± 0.01 0.50 ± 0.00 0.51 ± 0.00 
WWTP 7 INFL 0.45 ± 0.00 - - - 0.47 ± 0.00 
  EFFL 0.48 ± 0.00 - 0.49 ± 0.00 0.51 ± 0.00 0.50 ± 0.01 
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River Concentration [ng/L] 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 1.1 ± 0.1 <MQL <MQL <MQL 0.8 ± 0.1 1.2 ± 0.2 
After WWTP 1 2.8 ± 0.1 <MQL 7.6 ± 0.6 6.3 ± 0.1 14.9 ± 0.1 14.4 ± 1.1 
Before WWTP 3 1.5 ± 0.1 <MQL 3.5 ± 0.0 2.6 ± 0.1 9.3 ± 4.4 7.6 ± 0.8 
After WWTP 3 3.2 ± 0.2 1.2 ± 0.1 6.9 ± 0.6 5.9 ± 0.4 9.4 ± 4.6 11.4 ± 1.2 
Before WWTP 6 <MQL 8.4 ± 1.8 18.5 ± 0.6 21.7 ± 0.3 34.3 ± 0.3 40.6 ± 0.6 
After WWTP 6 <MQL 10.2 ± 1.3 26.5 ± 1.0 28.8 ± 0.3 39.1 ± 0.3 63.0 ± 5.8 
 
River Load [g/day] 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 - - - - - - 
After WWTP 1 - - - - - - 
Before WWTP 3 0.4 ± 0.0 <MQL 0.5 ± 0.0 0.4 ± 0.0 1.2 ± 0.6 0.6 ± 0.1 
After WWTP 3 0.9 ± 0.1 2.2 ± 0.2 1.0 ± 0.1 0.9 ± 0.1 1.3 ± 0.6 0.9 ± 0.1 
Before WWTP 6 <MQL 20.4 ± 4.5 18.7 ± 0.7 19.4 ± 0.3 26.4 ± 0.3 15.8 ± 0.2 
After WWTP 6 <MQL 25.8 ± 3.2 28.9 ± 1.1 28.1 ± 0.3 32.7 ± 0.3 28.7 ± 2.6 
River Enantiomeric fraction 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 0.40 ± 0.02 - - - 0.51 ± 0.03 0.50 ± 0.00 
After WWTP 1 0.47 ± 0.03 0.47 ± 0.08 0.47 ± 0.02 0.52 ± 0.00 0.50 ± 0.02 0.49 ± 0.00 
Before WWTP 3 0.50 ± 0.02 0.45 ± 0.00 0.53 ± 0.01 0.59 ± 0.04 0.51 ± 0.01 0.50 ± 0.01 
After WWTP 3 0.49 ± 0.02 0.48 ± 0.00 0.50 ± 0.00 0.51 ± 0.01 0.50 ± 0.01 0.52 ± 0.00 
Before WWTP 6 - 0.53 ± 0.00 0.55 ± 0.03 0.54 ± 0.00 0.55 ± 0.00 0.65 ± 0.01 
After WWTP 6 - 0.50 ± 0.07 0.51 ± 0.02 0.52 ± 0.00 0.55 ± 0.00 0.62 ± 0.01 
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Table S12. Concentrations and enantiomeric fractions of atenolol in WWTPs and receiving waters (Note:  chiral-LC-MS/MS method was used for both 
quantification of drugs and enantiomeric profiling; see Tab. S4 for validation parameters; concentrations and enantiomeric fractions represent mean values for 
duplicate samples, each analyzed three times). 
WWTPs Concentration [ng/L] 
JANUARY FEBRUARY MARCH APRIL AUGUST 
WWTP 1 INFL 7631.8 ± 136.0 4288.3 ± 809.0 16909.3 ± 1767.0 8997.3 ± 229.0 18446.8 ± 1660.6 
  EFFL 2007.0 ± 40.0 8280.3 ± 1814.0 18831.0 ± 0 3893.5 ± 233.0 3445.8 ± 464.9 
WWTP 2 INFL 7831.5 ± 710.0 15721.3 ± 480.0 7389.5 ± 491.0 14706.5 ± 1552.8 11216.3 ± 94.4 
  EFFL 4424.0 ± 345.0 3811.0 ± 0.0 4459.8 ± 422.0 3284.5 ± 58.0 2873.5 ± 299.8 
WWTP 3 INFL 8543.8 ± 734.0 12032.0 ± 162.0 8196.8 ± 162.0 12135.8 ± 230.9 19160.5 ± 352.1 
  EFFL 4854.5 ± 338.0 7605.5 ± 363.0 7140.0 ± 363.0 3761.5 ± 0.0 4521.0 ± 419.3 
WWTP 4 INFL 6524.3 ± 907.0 11216.3 ± 3.9 7705.5 ± 313.0 8325.5 ± 166.9 11362.0 ± 1465.4 
  EFFL 4505.5 ± 236.0 4628.3 ± 499.0 5921.5 ± 1353.0 2625.5 ± 601.7 3399.0 ± 201.5 
WWTP 5 INFL 6805.8 ± 95.0 7193.8 ± 20.0 - 5101.5 ± 242.5 5858.0 ± 176.1 
  EFFL 3833.5 ± 197.0 4580.5 ± 67.0 - 5770.3 ± 503.8 1480.3 ± 23.0 
WWTP 6 INFL 9995.5 ± 1826.0 - 13838.0 ± 1699.0 16560.5 ± 1540.6 16958.5 ± 301.9 
  EFFL 3790.0 ± 882.0 - 7229.5 ± 1464.0 5900.3 ± 1136.0 2079.0 ± 117.4 
WWTP 7 INFL 16745.5 ± 472.0 - 12907.3 ± 1528.0 13371.3 ± 1402.1 13717.5 ± 691.6 
  EFFL 11238.0 ± 0.0 - 5894.8 ± 1348.0 7403.3 ± 1512.0 4814.0 ± 771.5 
 
WWTP Enantiomeric Fraction 
JANUARY FEBRUARY MARCH APRIL AUGUST 
WWTP 1 INFL 0.43 ± 0.00 0.44 ± 0.01 0.43 ± 0.00 0.42 ± 0.01 0.44 ± 0.01 
  EFFL 0.48 ± 0.01 0.41 ± 0.03 0.43 ± 0.01 0.45 ± 0.07 0.44 ± 0.00 
WWTP 2 INFL 0.43 ± 0.01 0.40 ± 0.01 0.42 ± 0.00 0.41 ± 0.01 0.44 ± 0.01 
  EFFL 0.44 ± 0.00 0.42 ± 0.00 0.41 ± 0.00 0.41 ± 0.02 0.44 ± 0.02 
WWTP 3 INFL 0.44 ± 0.01 0.41 ± 0.00 0.38 ± 0.01 0.44 ± 0.02 0.43 ± 0.01 
  EFFL 0.47 ± 0.01 0.44 ± 0.00 0.45 ± 0.01 0.50 ± 0.07 0.43 ± 0.02 
WWTP 4 INFL 0.47 ± 0.06 0.42 ± 0.06 0.35 ± 0.02 0.35 ± 0.02 0.41 ± 0.02 
  EFFL 0.47 ± 0.01 0.45 ± 0.00 0.49 ± 0.02 0.48 ± 0.04 0.45 ± 0.02 
WWTP 5 INFL 0.41 ± 0.00 0.40 ± 0.01 - 0.39 ± 0.01 0.38 ± 0.01 
  EFFL 0.42 ± 0.01 0.43 ± 0.01 - 0.40 ± 0.01 0.45 ± 0.01 
WWTP 6 INFL 0.30 ± 0.04 - 0.33 ± 0.04 0.31 ± 0.05 0.42 ± 0.00 
  EFFL 0.47 ± 0.01 - 0.49 ± 0.01 0.45 ± 0.01 0.45 ± 0.01 
WWTP 7 INFL 0.42 ± 0.00 - 0.33 ± 0.03 0.32 ± 0.02 0.41 ± 0.01 
  EFFL 0.48 ± 0.00 - 0.61 ± 0.00 0.52 ± 0.02 0.46 ± 0.01 
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River Concentration [ng/L] 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 49.0 ± 12.9 16.3 ± 1.4 52.5 ± 3.9 156.4 ± 58.4 299.4 ± 76.1 319.8 ± 3.9 
After WWTP 1 224.2 ± 27.4 203.8 ± 35.3 349.5 ± 12.7 315.1 ± 59.0 309.5 ± 19.7 3048.5 ± 0.7 
Before WWTP 3 214.6 ± 12.1 114.2 ± 10.5 130.4 ± 29.3 242.9 ± 36.4 136.8 ± 34.4 1311.8 ± 86.6 
After WWTP 3 111.0 ± 2.1 123.9 ± 0.0 451.6 ± 85.1 599.7 ± 67.2 603.9 ± 106.4 1876.8 ± 161.6 
Before WWTP 6 - 747.0 ± 297.0 1145.0 ± 0.0 1129.8 ± 0.0 1071.4 ± 67.4 - 
After WWTP 6 - - 1723.3 ± 964.6 1402.0 ± 0.0 2329.0 ± 164.2 - 
 
River Loads [g/day] 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 - 
- 
- 
- 
- 
- 
- 
- 
= 
= 
- 
- After WWTP 1 
Before WWTP 3 57.7 ± 3.3 202.3 ± 18.6 17.8 ± 4.0 37.6 ± 5.6 18.1 ± 4.5 95.2 ± 6.3 
After WWTP 3 30.9 ± 0.6 220.7 ± 0.0 65.2 ± 12.3 96.3 ± 10.8 83.8 ± 14.8 145.1 ± 12.5 
Before WWTP 6 - - 
- 
1021.3 ± 0.0 868.2 ± 0.0 823.3 ± 126.2 - 
After WWTP 6 - 1678.5 ± 939.5 1173.1 ± 0.0 1300.2 ± 137.4 - 
River Enantiomeric fraction 
DECEMBER JANUARY FEBRUARY MARCH APRIL AUGUST 
Before WWTP 1 0.46 ± 0.11 0.46 ± 0.09 0.49 ± 0.03 0.56 ± 0.09 0.48 ± 0.01 0.47 ± 0.03 
After WWTP 1 0.48 ± 0.02 0.46 ± 0.05 0.43 ± 0.01 0.46 ± 0.01 0.41 ± 0.00 0.43 ± 0.00 
Before WWTP 3 0.41 ± 0.03 0.50 ± 0.02 0.43 ± 0.03 0.46 ± 0.02 0.51 ± 0.07 0.44 ± 0.01 
After WWTP 3 0.46 ± 0.01 0.50 ± 0.00 0.43 ± 0.00 0.48 ± 0.02 0.46 ± 0.02 0.44 ± 0.02 
Before WWTP 6 - 0.46 ± 0.02 0.46 ± 0.03 0.43 ± 0.00 0.39 ± 0.00 0.38 ± 0.03 
After WWTP 6 - 0.47 ± 0.03 0.46 ± 0.01 0.43 ± 0.00 0.39 ± 0.00 0.39 ± 0.00 
 
 
